Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* At least 18 years old.~* Histologically confirmed, FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.~* Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.~* No evidence of disease progression~* ECOG status of 0 or 2~* Able to swallow and retain oral medication.~* Adequate hematologic, hepatic, and renal system function as follows:~Hematologic~* Absolute neutrophil count (ANC) at least 1.5 X 10\^9/L~* Hemoglobin at least 9 g/dL (or 5.59 mmol/L)~* Platelets at least 100 X 10\^9/L~* Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN~* Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic~* Total bilirubin up to 1.5 X ULN~* AST and ALT up to 2.5 X ULN Renal~* Serum creatinine up to 1.5 mg/dL~Or, if greater than 1.5 mg/dL:~Calculated creatinine clearance at least 50 mL/min Urine Protein~* Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or \< 1.0 gram determined by 24- hour urine protein analysis.~* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.~Exclusion Criteria:~* Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy~* Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.~* Clinically significant gastrointestinal abnormalities~* Prolongation of corrected QT interval (QTc) \> 480 msecs~* History of any one or more cardiovascular conditions within the past 6 months prior to randomization~* Cardiac angioplasty or stenting~* Myocardial infarction~* Unstable angina~* Symptomatic peripheral vascular disease~  * Class III or IV congestive heart failure~* Poorly controlled hypertension~* History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization~* Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.~* Evidence of active bleeding or bleeding diathesis.~* Hemoptysis within 6 weeks prior to randomization.~* Endobronchial metastases.~* Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.~* Investigational or anti-VEGF anticancer therapy prior to study randomization.~* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib~* Invasive malignancies that showed activity of disease within 5 years prior to randomization

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): matched placebo tablet administered orally once daily for up to 24 months
- Pazopanib (Type: EXPERIMENTAL): Pazopanib tablet administered orally at 800 mg once daily for up to 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).